Leukocyte-reduced blood components in transfusion medicine. Current indications and prospects for the future.
Transfusion medicine is a rapidly evolving specialty, and efforts are ongoing to improve the safety and quality of blood component therapy. Leukocytes are known to be the cause of numerous adverse effects of transfusion therapy, and their removal from red cells and platelet components may be desirable in a variety of clinical settings. The various complications of transfusion that can be attributed to contaminating leukocytes and the benefits of leukocyte depletion are addressed in this article. Laboratory as well as clinical data are summarized.
Klapper
E B
EB
Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, California.
Goldfinger
D
D
D001424:Bacterial Infections / Q000209:etiology / Q000517:prevention & control; D016913:Blood Component Transfusion / Q000009:adverse effects; D005334:Fever / Q000209:etiology / Q000517:prevention & control; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007109:Immunity; D007962:Leukocytes / Q000276:immunology / Q000502:physiology; D008171:Lung Diseases / Q000209:etiology / Q000517:prevention & control; D014777:Virus Diseases / Q000209:etiology / Q000517:prevention & control